Logo image of OVID

OVID THERAPEUTICS INC (OVID) Stock Fundamental Analysis

NASDAQ:OVID - Nasdaq - US6904691010 - Common Stock - Currency: USD

0.6175  +0.05 (+8.91%)

After market: 0.64 +0.02 (+3.64%)

Fundamental Rating

3

Overall OVID gets a fundamental rating of 3 out of 10. We evaluated OVID against 572 industry peers in the Biotechnology industry. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, OVID is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OVID has reported negative net income.
In the past year OVID has reported a negative cash flow from operations.
OVID had negative earnings in 4 of the past 5 years.
OVID had negative operating cash flow in 4 of the past 5 years.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.66%, OVID is in the better half of the industry, outperforming 65.90% of the companies in the same industry.
With a decent Return On Equity value of -42.60%, OVID is doing good in the industry, outperforming 70.34% of the companies in the same industry.
Industry RankSector Rank
ROA -31.66%
ROE -42.6%
ROIC N/A
ROA(3y)-3.22%
ROA(5y)-38.25%
ROE(3y)-11.3%
ROE(5y)-61.22%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

OVID does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OVID has been increased compared to 1 year ago.
Compared to 5 years ago, OVID has more shares outstanding
There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.62, we must say that OVID is in the distress zone and has some risk of bankruptcy.
OVID has a worse Altman-Z score (-4.62) than 60.39% of its industry peers.
There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.62
ROIC/WACCN/A
WACC9.44%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

OVID has a Current Ratio of 5.66. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
OVID has a Current ratio of 5.66. This is comparable to the rest of the industry: OVID outperforms 59.33% of its industry peers.
OVID has a Quick Ratio of 5.66. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
OVID has a Quick ratio of 5.66. This is comparable to the rest of the industry: OVID outperforms 59.68% of its industry peers.
Industry RankSector Rank
Current Ratio 5.66
Quick Ratio 5.66
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

OVID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.88%, which is quite impressive.
OVID shows a strong growth in Revenue. In the last year, the Revenue has grown by 110.52%.
Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -68.56% on average per year.
EPS 1Y (TTM)31.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)110.52%
Revenue growth 3Y-68.56%
Revenue growth 5YN/A
Sales Q2Q%58.76%

3.2 Future

Based on estimates for the next years, OVID will show a decrease in Earnings Per Share. The EPS will decrease by -3.18% on average per year.
The Revenue is expected to grow by 130.51% on average over the next years. This is a very strong growth
EPS Next Y44.8%
EPS Next 2Y5.32%
EPS Next 3Y13.32%
EPS Next 5Y-3.18%
Revenue Next Year98.35%
Revenue Next 2Y5.24%
Revenue Next 3Y307.17%
Revenue Next 5Y130.51%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OVID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OVID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

OVID's earnings are expected to grow with 13.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.32%
EPS Next 3Y13.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OVID!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OVID THERAPEUTICS INC

NASDAQ:OVID (2/21/2025, 8:00:02 PM)

After market: 0.64 +0.02 (+3.64%)

0.6175

+0.05 (+8.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-17 2025-03-17/amc
Inst Owners57.73%
Inst Owner Change-96.58%
Ins Owners5.24%
Ins Owner Change0.06%
Market Cap43.85M
Analysts85.71
Price Target3.45 (458.7%)
Short Float %1.48%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)78.41%
Min EPS beat(2)3.83%
Max EPS beat(2)152.99%
EPS beat(4)3
Avg EPS beat(4)-38.39%
Min EPS beat(4)-333.89%
Max EPS beat(4)152.99%
EPS beat(8)6
Avg EPS beat(8)-14.73%
EPS beat(12)9
Avg EPS beat(12)-4%
EPS beat(16)11
Avg EPS beat(16)-2.35%
Revenue beat(2)2
Avg Revenue beat(2)115.67%
Min Revenue beat(2)94.64%
Max Revenue beat(2)136.7%
Revenue beat(4)4
Avg Revenue beat(4)130.33%
Min Revenue beat(4)94.64%
Max Revenue beat(4)146.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.78%
PT rev (3m)3.78%
EPS NQ rev (1m)-0.34%
EPS NQ rev (3m)10.69%
EPS NY rev (1m)0%
EPS NY rev (3m)6.76%
Revenue NQ rev (1m)-1.24%
Revenue NQ rev (3m)215.48%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)41.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 69.43
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.01
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.66%
ROE -42.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.22%
ROA(5y)-38.25%
ROE(3y)-11.3%
ROE(5y)-61.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.59%
Cap/Sales 32.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.66
Quick Ratio 5.66
Altman-Z -4.62
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)134.73%
Cap/Depr(5y)120.84%
Cap/Sales(3y)42.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y44.8%
EPS Next 2Y5.32%
EPS Next 3Y13.32%
EPS Next 5Y-3.18%
Revenue 1Y (TTM)110.52%
Revenue growth 3Y-68.56%
Revenue growth 5YN/A
Sales Q2Q%58.76%
Revenue Next Year98.35%
Revenue Next 2Y5.24%
Revenue Next 3Y307.17%
Revenue Next 5Y130.51%
EBIT growth 1Y-30.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.83%
EBIT Next 3Y-5.26%
EBIT Next 5YN/A
FCF growth 1Y2.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.47%
OCF growth 3YN/A
OCF growth 5YN/A